bluuebunny/crossref_metadata_2025_split huggingface dataset:
Prognostic value of serum Cytokeratin19-2G2 in primary breast cancer patients.
Authors: Xie Xiaoming , Kong Yana , Dai Shuqin , Liu Wanli , Wei Weidong 
Published: March 2020

e11091 Background: Cytokeratin19-2G2, one of cytokeratin19 fragments, has been considered as one of the most sensitive tumor markers. However, no previous studies reported of CK19-2G2 in breast cancer. The purpose of our study is to evaluate the prognostic value of CK19-2G2 in primary breast cancer patients. Methods: This study included 249 primary breast cancer patients with stage 0-III, 81 healthy controls and 21 breast benign disease patients. Serum samples were conserved before surgery. CK19-2G2, CEA and CA153 were measured by chemiluminescent assay and ER, PR, CerbB2 were assessed by Immunohistochemistry assay. Results: Serum CK19-2G2 levels in breast cancer patients were significantly higher than that in healthy and benign controls (P < 0.001). High serum CK19-2G2 levels (≥2 ng/mL) were associated with stage III (P < 0.001), tumor size (≥2cm) (P < 0.001), lymph node involvement (P < 0.001), negative estrogen receptor (P = 0.005) and progesterone receptor status (P = 0.001). Multivariate analysis revealed that high serum CK19-2G2 level was an independent factor for relapse (P = 0.029) and death (P = 0.040) in primary breast cancer patients. Conclusions: High serum CK19-2G2 levels maybe considered as an independent indicator for prognosis in primary breast cancer.
Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use.
Authors: Aksoy Sercan , Sendur Mehmet Ali Nahit , Yaman Sebnem , Arik Zafer , Ozdemir Nuriye , Zengin Nurullah , Altundag Kadri 
Published: March 2020

e11093 Background: Bisphosphonates therapy reduces the risk of skeletally related complications in patients with bone metastases due to malignancy and bisphosphonates are the most common used agents in the treatment of osteoporosis. However, the effect on clinical and pathological properties of breast cancer with using oral alendronate has not been reported. We investigate retrospectively the demographic and clinico-pathological characteristics of patients with oral alendronate users for longer than 1 year, compared to non-users. Methods: Patients with breast cancer diagnosed from 1998 to 2010 in our clinic were retrospectively analyzed. Patient’s demographics including survival data and tumor characteristics were obtained from medical charts. Breast cancer patients who were taking oral alendronate more than 12 months at the time of breast cancer diagnosis were enrolled as an alendronate users (n=44), where the patients matched with the same age who were not taking oral alendronate were included as a control group (n=444). Results: A total of 488 patients were included in this study. Forty-four patients received an oral alendronate treatment more than one year and 444 patients were considered as nonusers. Median age of both alendronate users and nonusers was 57 (33-89). Lower incidence histological grade III, T3-T4 tumor, and node positivity was seen in alendronate users but not statistically significant. A similar trend for lower incidence of triple negative and higher incidence ER (P=0.13), PR (P=0.12) and HER2 positivity (P=0.21) was also seen in alendronate users but not statistically significant. Disease free survival rate was 150±28 months in alendronate users where as 70±24 months in nonusers (P=0.015). Median overall survival rates could not be obtained but higher in alendronate users but not statistically significant (P=0.13). Conclusions: The use of oral alendronate for longer than one year before the diagnosis of breast cancer was associated with better clinico-pathological properties and significantly improved disease free survival in breast cancer patients.
Strategies for promoting advocacy engagement in the Bay Area Physical Sciences Oncology Center (PS-OC) setting.
Authors: Samson Susan , Vincent Linda V. , Klein Connolly Hannah , Acerbi Irene , Weaver Valerie , Rugo Hope S. 
Published: March 2020

e11096 Background: Bay Area physical sciences researchers, supported by funding from the National Cancer Institute (NCI), encourage broad thinking to tackle the variability of breast cancer and to address data gaps in breast cancer prevention, emergence, behavior, and treatment. Methods: In this transdisciplinary innovation focused scientific arena, the Bay Area PS-OC also established the groundwork work for engaging advocates in the research programs. Results: Emerging results of this research collaboration: (1) Promote the integration of advocates into PSOC culture:Engage the perspectives of advocates to sensitize researchers to patient needs/concerns, and to encourage disruptive change in the interests of saving lives. Encourage front end inclusion of advocates in program planning and research design. (2) Create new pathways for the translation and dissemination of information: Utilize new internet technology and transdisciplinary collaboration models to help promote science literacy and communicate the implications of a mechanics-centric view of cancer. Reconfigure consumer expectations regarding the benefits of physical sciences approaches and highlight how this cutting edge science informs translational research in both cancer prevention and therapeutics. (3) Pilot an Advocate Mentor Program: Train the next generation of professionals, and specifically engage advocates in cross sector convergence collaborations with scientists, post-doctoral fellows, students, and clinicians. Conclusions: Some of the most exciting transdisciplinary engagement lies at the intersection of disciplines when all stakeholders (scientists, clinicians, and advocates) collectively consider new approaches and strategic processes that point to synergies of interest, thorny issues, capacity building, metrics and measures, and new engagement theories. Supported by: grant U54CA143836-01 from the NCI to VMW and JL; NCI SPORE P50 CA058207 to VMW, CP, & SH; U01 ES019458-02 to ZW.
Comparison of neoadjuvant systemic treatment (chemotherapy with or without trastuzumab) responses with dynamic contrast-enhanced breast magnetic resonance imaging and histopathology in locally advanced breast cancer.
Authors: Orbay Ozge , Demirkan Hatice Mirac Binnaz , Balci Pinar , Durak Merih , Saydam Serdar 
Published: March 2020

e11507 Background: It is reported that dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may have the potential of predicting response to neoadjuvant chemotherapy (NAC) for patients with breast cancer and it is more accurate than the other radiologic methods. We aimed to compare the responses to NAC ± trastuzumab with DCE-MRI and histopathologic findings in locally advanced breast cancer. Methods: Between January 2007 and October 2011, 38 female patients patients with locally advanced breast cancer who recieved NAC ± trastuzumab and had whole breast DCE-MRI before / after treatment and who also had surgery after treatment were included in our study. Patients received 4 cycles of antracyclin based and 4 cycles of taxane based chemotherapy protocols sequentially. 9 patients with HER-2 (+) breast cancer also received trastuzumab with taxane based chemotherapy. Before and after NAC ± trastuzumab, tumor measurements were evaluated by mammography (MG), ultrasound (US), DCE-MRI and compared with postoperative histopathologic findings. Response rates were assessed with RECIST (Response Evolution Criteria in Solid Tumors) 1,1 criteria. MRI were done with 1,5 Tesla MR ( Gyroscan Achieva Intera, Philips ). SPSS 15.0 and Kappa test were used for statistical analysis. Results: After NAC ± trastuzumab, breast DCE-MRI revealed 13.2% complete response (CR), 73.7% partial response (PR), 10.5% stabile disease (SD), and 2.6% progressive disease (PD) and 15.8% CR, 73.7% PR, 7.9% SD and 2.6% PD were shown with histopathology. After neoadjuvant systemic treatment, histopathologic and DCE-MRI responses revealed high positive correlation with kappa test (kappa: 0,63), but there were low correlation between not only histopathologic and MG responses but also US responses with kappa test (kappa: 0,2). Conclusions: DCE-MRI is more effective method than other radiologic methods for the evaluation of response to NAC ± trastuzumab when compared with the histopathologic findings.
Prognosis of breast cancer in patients with peritoneal metastasis.
Authors: Petekkaya Ibrahim , Ayyildiz Veysel , Kizilarslanoglu Cemal , Sahin Ugur , Gezgen Gamze , C. Roach Emir , Karcaaltincaba Musturay , Altundag Kadri 
Published: March 2020

e11509 Background: Distant spread from breast cancer is commonly found in bones, lungs, liver, and central nervous system. However, peritoneal involvement is unusual and unexpected. The aim of the study was to perform a comprehensive analysis of breast cancer patients with peritoneal metastases. Methods: Twenty-one (0.9% of the cohort) breast cancer patients with peritoneal metastases were detected out of a database of 2,219 breast cancer patients treated in Hacettepe University Medical Oncology Department. Clinical characteristics, follow up times and survival rates were analyzed. Results: The mean age of the 21 patients at the time of peritoneal metastasis was 56 years (38-71). 12 (57.1%) patients were post-menopausal, 6 (28.6%) patients were pre-menopausal. Numbers of deceased patients were 7 (33.3%). Seven (33.3%) patients’ histological subtypes were invasive ductal carcinoma (IDC), five (23.8%) patients’ were invasive lobular carcinoma (ILC) and three (14.3%) patients’ were mixed (IDC and ILC). Numbers of luminal A patients were 8 (38.1%), luminal B were 5 (23.8%), triple negative were 2 (9.5%). There was no Her-2 overexpressing patient and numbers of unknown molecular subtype patients were 6 (28.6%). The median follow up times after peritoneal disease in patients deceased and living were 9.3 (range: 0.4-23.3) months and 15.6 (range: 0.3-40.4) months, respectively. Median follow up time after peritoneal metastasis of ER positive patients was 13.7 months, and it was longer than ER negative patients (4.4 months). Six months and one year survival rates after peritoneal metastasis were 83.3% and 73.3%, respectively. Disease free, progression free and overall survival data could not be obtained due to inadequate number of events. Conclusions: Peritoneal metastasis of breast cancer is very rare and median survival time is controversial in literature. Despite of a small cohort, we found the patients’ follow up times longer than reported before. Especially, ER positive patients have longer survival time than ER negative, and this result highlights the importance of hormonotherapies.
Incidence and implications of oligometastatic breast cancer.
Authors: Jain Supriya K. , Dorn Paige L. , Chmura Steven J. , Weichselbaum Ralph R. , Hasan Yasmin 
Published: March 2020

e11512 Background: There is increasing evidence that prolonged disease control is possible in patients with a limited number of metastatic sites compared to those with more diffuse disease, especially when aggressive local therapy (surgery and/or stereotactic radiation) is administered. The objective of this study is to describe the frequency of oligometastatic breast cancer in patients who develop distant disease and to characterize their disease course. Methods: A retrospective review was performed of a tri-institutional database of Stage I-III breast cancer patients treated from 1978 to 2005. Patients were categorized as "oligometastatic" (OM) if ≤ 5 sites of disease were identified at time of first failure or “polymetastatic” (PM) if failure occurred at > 5 sites. Patients were followed for ≥ 3 y after first metastasis, until death, or until development of > 5 sites of metastatic disease. T and N stage, hormone receptor status, presenting symptoms of metastasis, number and site of metastases, actuarial overall survival (OS), and overall survival after first failure (OSAF) were examined. Kaplan-Meier, chi-square, and log-rank tests were used for statistical analysis. Results: Of 2,249 patients reviewed, 114 (5.1%) failed at distant sites and met inclusion criteria. The OM phenotype was observed in 21.9% (25/114). Of patients presenting with symptoms of metastasis, 18.3% were OM, whereas patients with metastases identified incidentally or by screening were OM in 42.1% of cases (p = 0.02). Median OSAF was significantly longer in OM patients (44.7 mos) than PM patients (18.1 mos) with 5 y OS of 48.5% and 10.7% respectively (p < 0.001). Outcome of OM patients compared favorably to that of patients with bone-only metastases in whom the median OSAF was 25 mos and 5 y OS was 12.5%. Baseline features of OM and PM patients did not differ according to initial tumor size (p = 0.94), nodal stage (p = 0.5), or ER+ (p = 0.28). Conclusions: A significant proportion of early stage breast cancer patients with distant failure will have OM disease, and this subset is expected to have prolonged overall survival. The relatively favorable prognosis of patients with OM disease warrants consideration of aggressive local therapy and may have implications in the design of future clinical trials.
Inflammatory breast cancer in Morocco: Experience of Hassan II University Hospital.
Authors: Daoudi Khaoula , Brahmi Sami Aziz , Boudahna Lamie , Hijri Fatima Zahra , Bouyahia Nezar , Oulla Karima , Benhammane Hafida , Chad Amine Mohammed , El mrabet Fatima Zahra , Arifi Samia , Nawfel Mellas , El Mesbahi Omar 
Published: March 2020

e11516 Background: Inflammatory breast cancer (IBC) is the most virulent type of breast cancer. It represents 1 to 6% of all the breast cancer in Western countries. It is speculated that the incidence of IBC is greater in emerging countries especially in North Africa. The management of this disease requires a multidisciplinary. Methods: We recorded the cases of 80 patients with IBC admitted in the Medical Oncology Unit between January 2007 and August 2011. We included patients with IBC classified as T4d using criteria based on the tumor-node-metastasis (TNM) classification . The aims of this study is to evaluate the epidemiological, clinical, histopathological and therapeutic aspects of this disease. Results: The median age of our patients was 44.5 years ranged from 24 to 88 years. The incidence of IBC in our study was 7.8%. The lymph node involvement was noted in 60% distributed as following: N0 in 40%, N1 in 30%, N2 in 19%, N3 in 11%. For histology, ductal carcinoma represents 96% of all cases. Human epithelial receptor 2 (HER 2) was positive in 32% of the cases. Hormonal receptors were negative in 22% of the cases. The grade of the tumor according to the Scarff Bloom Richardson classification was as following: grade I ( 2.5%), grade II (52%), grade III (45.5%). All patients received neoadjuvant chemotherapy. 45% received chemotherapy with anthracyclines, 35% were treated with docetaxel and anthracycline and 10% with the association chemotherapy Trastuzumab. According to RECIST classification, a partial or total clinical response was noted in 80% of cases, 10% of patients had stability, and 10% clinical progression. According to Sattalof classification, a histological response greater than 50% in the tumor (TB) was noted in 45%. A complete pathological response (TANA or TANB) was obtained in 15% of cases. After a median follow up of 2 years 35% of the patients had a metastatic or locoregional reccurence, 45% of the cases remain in complete remission. Conclusions: The result of our study is concordant with the litterature. The incidence of IBC was greater than the incidence in western countries. The IBC was also associated with high grade and younger age. Despite a good clinical and pathological response to chemotherapy, outcomes were poor.
Clinicopathologic characteristics of triple-negative breast cancer and relationship to basal markers.
Authors: Tryfonopoulos Dimitrios , Oikonomopoulos Georgios , Demiri Stamatina , Lekakis Lazaros , Pistamaltzian Nikolaos Fragkiskos , Koumakis George , Panopoulos Chris G. , Koufopoulos Nektarios , Apostolikas Nikiforos , Misitzis Ioannis , Efremidis Anna P. 
Published: March 2020

e11519 Background: Triple negative breast cancers are immunohistochemical surrogates of basal-like breast cancers. There is no complete overlap between triple negative and basal-like tumors and as gene expression studies evolve, further subclassification bearing clinical relevance is underway. Our purpose was to correlate clinicopathologic characteristics of triple negative breast cancer tumors with expression of basal markers in an effort to define immunohistochemically subgroups of this heterogenous disease Methods: Data were retrieved and analysed using our electronic databank. Patient samples were reviewed by an expert breast cancer pathologist and stained additionally for EGFR and CK 5/6 antibodies. Results: Sixty-five women with triple negative breast cancer were identified. Mean age was 58.3±12.9 years. Most tumors (86%) were of ductal histology, 53% grade 3, 48% having high Ki-67 index (>14%). 10% of patients presented with Stage IV, 25% with Stage III, 38% with stage II and 27% with stage I disease. 63% of patients were postmenopausal. EGFR staining was present in 43% of tumor samples, whereas CK 5/6 in 38.5%. Both EGFR and CK 5/6 expression was found in 18.5%, whereas 37% of tumors expressed neither EGFR or CK 5/6. No difference was observed between tumors expressing any of these 2 basal markers as compared to EGFR and CK 5/6 negative tumors in terms of Ki-67 index, grade, tumor size and nodal involvement. Lymphovascular invasion and non-ductal histology tended to occur more frequently (p=ns) in non-basal tumors. Additionally, patients with expression of any of the basal markers tended to be more obese than the non-basal triple negative breast cancer patients (p=ns). Conclusions: Further immunohistochemical markers apart from EGFR and CK 5/6 are needed in order to further define clinically meaningful subgroups of triple negative breast cancer.
Bevacizumab plus chemotherapy in the treatment of metastatic breast cancer: Hospital of Cruces experience.
Authors: Ferreiro Josefa , Ruiz de Lobera Abigail , Sancho Aintzane , Carrera Sergio , Marrodan Ines , Rubio Itziar , Iruarrizaga Eluska , Azkona Eider , Munoz Llarena Alberto , Lopez-Vivanco Guillermo 
Published: March 2020

e11525 Background: Antiangiogenic therapies such as bevacizumab (BV), have proven to be effective in improving outcomes in metastatic disease from several tumor types. For metastatic breast cancer (MBC), combinations of BV and established chemotherapy regimens potentially offer new, more efficacious treatments without the significant toxicity associated with combining multiple cytotoxic agents. Methods: This is a retrospective chart review that reflects Hospital of Cruces experience with BV in combination with chemotherapy in patients with MBC. Demographic and treatment data were collected from diagnosis and follow-up period. Results: A total of 66 patients were included. Median age was 53(34-78) years. ECOG PS 0/1/2/3 was 35%/51.5%/10.5%/3%, respectively. Positive hormone receptor (66.7%) and negative hormone receptor (33.3%). Her2 negative and triple negative were 100% and 33.3% of the patients. Adjuvant treatment received was 81.8% chemotherapy and 56.1% hormone therapy. Most frequent metastasis locations: bone (68%), liver 54.5%, lymph nodes (51.5%) and lung (27.3%). Thirty-five patients reported two or 3 metastasis locations. Chemotherapy used with BV was docetaxel (68.2%) and paclitaxel (31.8%). Median of BV courses was 6 (1-20). Response rate was 57.5% (53% partial response) and 28.8% had stable disease. Median Progression Free Survival (PFS) was 11.7 months and median OS was 19.7 months. Statistical differences were observed between patients who received a maintenance therapy with BV vs patients who received no maintenance therapy (PFS: 9.34 vs 15.36 months, p<0.001; OS: 13.81 vs 25.56 months, p<0.001). Most frequent toxicities 3/4 were: neutropenia 31.8%, febrile neutropenia 21.2%, asthenia 21.2%, infection 9.1% and onycholysis 6.1%. Conclusions: BV in combination with chemotherapy improves clinical benefit in terms of increased PFS and OS in first-line treatment of metastatic breast cancer. Maintenance with BV revealed statistical differences. Toxicity profile was manageable and as expected for BV.
Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer.
Authors: Singh Jasmeet Chadha , Stein Stacy , Volm Matthew , Smith Julia Anne , Novik Yelena , Speyer James L. , Meyers Marlene , Adams Sylvia , Omene Coral Oghenerukevwe , Muggia Franco , Schneider Robert , Formenti Silvia , Davis Samantha , Beardslee Brian , Tiersten Amy 
Published: March 2020

e11529 Background: Triple negative breast cancer cells are unable to repair double stranded DNA breaks and hence have sensitivity to platinum agents. Rapamycin acts synergistically with platinum agents to induce apoptosis and inhibit proliferation in breast cancer cell lines. Combination of RAD001 (oral mTOR inhibitor) and Carboplatin may have activity in triple-negative breast cancer. Methods: The primary objective of the study was to estimate the clinical benefit (complete remission (CR) + partial remission (PR) + stable disease (SD) >6 months) and the toxicity of this combination in women with triple negative metastatic breast cancer who have had 0-3 prior chemotherapy regimens for metastatic disease. 25 subjects were to be entered into a single stage open label Phase II study. Prior Carboplatin is allowed. Treated brain metastasis are eligible. The null hypothesis that the clinical benefit rate is ≤10% could be rejected if number of CR/PR/SD >6 months was ≥6. Originally, intravenous Carboplatin AUC 6 was to be administered every 3 weeks along with daily 5mg of RAD001 with a 3 patient run-in and then 10 mg daily. Due to a surprising amount of thrombocytopenia with this combination, the dose of Carboplatin was first amended to AUC 5 and most recently to AUC 4 with 5 mg of RAD001. Results: 18 patients have been recruited thus far. Median age is 59. There have been 1 CR, 4 PR’s and 2 SD's lasting > 6 months. One SD was achieved in a patient progressing on single agent Carboplatin at study entry. Median duration of CR+ SD +PR thus far is 13 weeks (range: 6-60 weeks). 5 patients had grade 3/4 thrombocytopenia and 4 patients had grade 3 neutropenia (no febrile neutropenia). However, since amendment of Carboplatin dose to AUC 4 the regimen has been well tolerated. 1 patient suffered from grade 3 dehydration. The estimated clinical benefit rate is 50% (95% C.I.: 24%, 76%). Median time to progression or death is 87.5 days from start of treatment; there is only 1 death to date on this study. Conclusions: The study has achieved it’s primary objective of demonstrating clinical benefit of RAD 001-Carboplatin combination in triple negative metastatic breast cancer. Dose limiting thrombocytopenia was an unexpected side effect requiring protocol amendment.